The antibiotic eye drop Azasite (azithromycin ophthalmic solution 1%; Akron Inc.) is currently unavailable due to a delay in shipping of the drug, according to the Food and Drug Administration (FDA).
Azasite, a macrolide antibiotic, is indicated for use in bacterial conjunctivitis caused by susceptible isolates of the following microogranisms: CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae.
The product is anticipated to become available again in October 2018.
For more information visit FDA.gov.
